AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02895815 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CNTO 2476 (6.0 * 10^4 cells)
Description: Participants will receive a single subretinal administration of CNTO 2476 (6.0 \* 10\^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit \[SRAK-02 kit\] and third arm accessory).
Study NCT02895815 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CNTO 2476 (3.0 * 10^5 cells)
Description: Participants will receive a single subretinal administration of CNTO 2476 (3.0 \* 10\^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
Study NCT01649713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluval AB vaccination
Description: Vaccination with Fluval AB suspension for injection
Study NCT02178098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 capsules taken once daily
Study NCT02178098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken once daily
Study NCT04243980 — intervention group
Intervention type: DEVICE
Intervention: Short anatomical femoral stem in THR
Description: Patients with osteoarthritis after total hip arthroplasty
Study NCT00285844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss
Study NCT02524587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard polyethylene acetabular irradiated at 3 Mrad
Study NCT02524587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radio stereometric analysis (RSA) of the acetabular
Study NCT00285844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiazolidinedione
Study NCT03707886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain SMART
Description: Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.
Study NCT03707886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: minimally enhanced usual care
Description: The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
Study NCT02765399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT02765399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03084718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 718 pMDI
Description: Dose Response: Test one of three different doses of CHF 718 pMDI
Study NCT03084718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pMDI
Description: Placebo Control
Study NCT03084718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone Dipropionate (BDP)
Description: Active Control
Study NCT01503580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine, solifenacin
Description: The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
Study NCT01152736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 2 mg Single-dose
Study NCT01152736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 2 mg Single-dose
Study NCT02331524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Feedback and Encouragement
Description: The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!
Study NCT03243227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic techniques
Description: 4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
Study NCT03243227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: AROM exercise stretching exercise strengthening exercise 4 sessions
Study NCT03484728 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo manipulation
Description: application of nonactive body cream on forearm
Study NCT03484728 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: placebo manipulation
Description: application of nonactive body cream on forearm
Study NCT03272555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WILD 5 Wellness Interventions
Description: Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
Study NCT01203709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose combination of MMF and Tac
Description: mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
Study NCT01601184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
Study NCT01601184 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vismodegib
Description: Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
Study NCT01601184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
Study NCT01601184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
Study NCT02067507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored education and referral
Description: LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
Study NCT02067507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff training and patient reminders
Description: AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
Study NCT02067507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-level reminder systems
Description: Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
Study NCT00688857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline
Description: Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
Study NCT00688857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline
Description: Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
Study NCT02737501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets
Study NCT02737501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Crizotinib tablets
Study NCT01252082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Rootplaning
Description: All patients in the test group receive scaling and rootplaning under local anesthesia
Study NCT02582827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-011
Description: ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
Study NCT00741169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350
Description: 200 mg taken by mouth once daily for 7 days
Study NCT00826657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: 500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
Study NCT00741169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg taken by mouth once daily for 7 days
Study NCT00826657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
Study NCT02940951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPSS
Description: Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
Study NCT02940951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Home healthcare services provided by nurses and, where applicable, multi-professional teams.
Study NCT02940951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Home healthcare services provided by nurses and, where applicable, multi-professional teams.
Study NCT04156789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Home sleep apnea testing
Description: Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
Study NCT00301652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: MMF,1.0g/d
Study NCT03336515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group C-Postural device activated
Description: General recommendation not sleeping in supine position and the postural device activated (intervention group).
Study NCT02331524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Coaching/Home Exercise
Description: The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
Study NCT01057914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with a liquid formula
Description: The patient consumes 400 kcal from a liquid supplementation formula
Study NCT01057914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: The patient receives dietary advice for one hour during the hospital stay.
Study NCT01057914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of supplement and dietary advice
Description: The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
Study NCT00741169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350+rifampin
Description: The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
Study NCT01742078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV
Study NCT01742078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - SC
Description: Administered SC
Study NCT03336515 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Group B-Postural device no activated
Description: General recommendation not sleeping in supine position and the postural device without any activation (placebo)
Study NCT02234765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care-based management
Description: Patients will be diagnosed and follow-up in Primary Care.
Study NCT03336515 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group A-General Recommendation
Description: General recommendation not sleeping in supine position
Study NCT01742078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV or SC
Study NCT03400137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Increasing of intraocular pressure (IC)
Description: intraocular pressure will be increased using an ophthalmodynanometer
Study NCT02608034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
Study NCT02608034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
Study NCT02608034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible bronchoscopy in moderate sedation
Description: Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible bronchoscopy in moderate sedation
Description: Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
Study NCT02234765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard management
Description: Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen saturation
Description: Continuous measurement of oxygen saturation;
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen saturation
Description: Continuous measurement of oxygen saturation;
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure
Description: Measurement of non-invasive blood pressure every 3 minutes
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Measurement of non-invasive blood pressure every 3 minutes
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propofol dosage
Description: Report of dose adjustments und cumulative propofol dosage;
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propofol dosage
Description: Report of dose adjustments und cumulative propofol dosage;
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recovery time after bronchoscopy
Description: Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
Study NCT02246023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recovery time after bronchoscopy
Description: Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
Study NCT03451500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa
Description: See previous
Study NCT03451500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carbidopa-levodopa
Description: See previous
Study NCT02116816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol
Description: Polyphenol
Study NCT00185887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline
Description: Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
Study NCT03198780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Awareness
Description: Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
Study NCT02026206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level light therapy
Description: we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
Study NCT02026206 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
Study NCT00440817 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: All treatments are prescribed by a physician on the basis of usual clinical practice.
Study NCT04873076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction using 2d video glasses from HappyMed GmbH
Description: Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
Study NCT02524587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acetabular polyethylene vitamys®
Study NCT03276780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
Study NCT03276780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
Study NCT03276780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination NRT
Description: Both groups will receive combination NRT to help with smoking cessation
Study NCT03276780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination NRT
Description: Both groups will receive combination NRT to help with smoking cessation
Study NCT03667079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated delivery of deworming and vaccination
Description: integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
Study NCT03667079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mass deworming only
Description: Delivery of mass deworming to people only
Study NCT03667079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mass vaccination of dogs
Description: Delivery of mass vaccination of dogs only
Study NCT01689662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m EC20
Study NCT01429051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Fentanyl Spray (INFS)
Description: Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
Study NCT01429051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching intranasal placebo spray
Study NCT03589235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A free gingival graft
Description: A free gingival graft will be used for the treatment of gingival recession